Elexacaftor-Tezacaftor-Ivacaftor and Ivacaftor (Trikafta®) for the Treatment of Cystic Fibrosis (CF) in Children Ages 2+
Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for elexacaftor-tezacaftor-ivacaftor and ivacaftor (Trikafta) for for the treatment of cystic fibrosis (CF) in children ages 2+ who have at least one F508del mutation in the CF transmembrane conductance regulator (CFTR) gene or a mutation in the CFTR gene that is responsive based on in vitro and/or clinical data.